Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), presented data on its specific pGlu3-Abeta monoclonal antibody at Neuroscience 2015, the 45th annual meeting of the Society for Neuroscience (SfN) in Chicago, USA.
The data presented result from a collaboration between Probiodrug and the research team led by Associate Professor Cynthia Lemere from the Center for Neurologic Diseases at the Brigham and Women’s Hospital and Harvard Medical School, Boston (MA, USA).
The oral presentation entitled “Preclinical in vivo Effects of an anti-PyroGlu-3 Abeta Antibody” was presented on Saturday, 17 October 2015 at 1.45 pm CDT in S403. The abstract was selected for presentation in the Nanosymposium 11, Alzheimer’s Disease: Experimental Therapeutics.
Pyroglutamate-3 Abeta (pGlu-3 Abeta), a post-translational modified Abeta, is a highly toxic Abeta variant that is abundant in the brains of patients with AD. The therapeutic study investigated the role of the antibody’s IgG isotype on efficacy and safety in 16-month-old APP/PS1 dE9 mice, following passive immunization for four months.
The IgG2a version showed a robust significant reduction in cerebral pGlu3-Abeta, general Abeta as well as Abeta plaque load, which was paralleled by a significant improvement in learning and memory in water T-maze tests. These effects were significantly more pronounced compared with those of an IgG1 isotype of the antibody.
This is the first report that an anti-pGlu-3-Abeta approach not only reduces Abeta/plaques but also significantly improves cognitive deficits in aged Alzheimer’s mice. Moreover no evidence was found for increased microhemorrhages after treatment.
Dr Inge Lues, Chief Development Officer at Probiodrug, commented: “The results show that in preclinical studies, immunotherapy with the IgG 2a isoform of the pGlu3-Abeta antibody is effective in lowering plaque burden in the absence of microhemorrhage, while improving cognitive performance. These results were important for the selection of the IgG-subtype of PBD-C06, our development candidate that is now in preclinical development.”